ACHV Achieve Life Sciences Inc.

12.22
-0.47  -4%
Previous Close 12.69
Open 12.53
52 Week Low 4.51488
52 Week High 18.26
Market Cap $74,421,804
Shares 6,090,164
Float 6,072,487
Enterprise Value $52,130,000
Volume 255,831
Av. Daily Volume 342,987
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Cytisine - ORCA-2
Smoking cessation
Phase 3
Phase 3
Phase 3 trial initiation announced October 7, 2020.

Latest News

  1. SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / February 24, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that three posters featuring data on smoker and e-cigarette user behavior will be presented today, Wednesday, February 24th at the SRNT Annual Meeting being held virtually. An overview of the data can be also accessed by visiting https://ir.achievelifesciences.com/srnt2021.

    Poster Highlights

    • "A Survey in the United States of Attitudes to Nicotine Cessation in Smokers: Smokers' Satisfaction with Available Treatments" (PH-293): Results from a recent survey of 1,122 current…

    SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / February 24, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that three posters featuring data on smoker and e-cigarette user behavior will be presented today, Wednesday, February 24th at the SRNT Annual Meeting being held virtually. An overview of the data can be also accessed by visiting https://ir.achievelifesciences.com/srnt2021.

    Poster Highlights

    • "A Survey in the United States of Attitudes to Nicotine Cessation in Smokers: Smokers' Satisfaction with Available Treatments" (PH-293): Results from a recent survey of 1,122 current and former smokers indicated the overall satisfaction and perceived efficacy of available cessation treatments was low. A majority of smokers who use prescription medications to quit smoking do not complete the 3-month course of therapy and concerns about side effects are reported as the key reason for non-compliance, or refusal to initiate treatment with Chantix® (varenicline) or bupropion.
    • "A Survey in the United States of Attitudes to Nicotine Cessation in Vapers: Reasons for Choosing to Vape" (PH-294) Survey results from 508 users of nicotine vape products showed that the primary reason to initiate e-cigarettes/vaping was to quit combustible cigarettes. While proven successful in the cohort of subjects who only utilize vape, dual users, those who vape but also continue to smoke, reported 2-times heavier nicotine use than their counterparts. These data suggest that dual users become more heavily addicted to nicotine due to vaping.
    • "A Survey in the United States of Attitudes to Nicotine Cessation in Vapers: Their Plans to Quit Vaping" (PH-295) Data from 508 users of nicotine vape products indicated that 73% of e-cigarette/vape users intend to quit vaping in the next 3-12 months. Of those who intend to do so in the next 3 months, more than half reported they would be "very/extremely likely to try a new prescription product" to help them quit.

    "This real-world evidence supports the critical need for a new therapeutic option for smokers and e-cigarette users who are unable to tolerate, or refuse to take, currently available treatments due to side effects or negative product perceptions," commented John Bencich, CEO of Achieve. "We know that more than 75% of Chantix users are not completing the 3-month treatment, and we believe the tolerability profile of cytisinicline, as shown in trials to date, may help smokers remain on treatment and lead to better outcomes for those battling nicotine addiction."

    Achieve is currently enrolling smokers in the 750-subject, Phase 3, ORCA-2 study of cytisinicline at 15 sites the U.S. For more information on cytisinicline and the ORCA-2 study, visit www.achievelifesciences.com or www.orca-2.com.

    About Achieve and Cytisinicline
    Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the U.S. annually.1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2

    Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.

    Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

    Cytisinicline is an investigational product candidate being developed for treatment of nicotine addiction, and has not been approved by the FDA for any indication in the U.S.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing and nature of cytisinicline clinical development activities, the potential market size and market acceptance for cytisinicline, the potential benefits of cytisinicline and the development and effectiveness of new treatments. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

    Media Contact

    Glenn Silver

    (646) 871-8485

    Investor Relations Contact
    Jason Wong

    (415) 375-3340 ext. 4

    References

    1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.
    2 U.S. Department of Health and Human Services. The Health Consequences of Smoking - 50 Years of Progress. A Report of the Surgeon General, 2014.

    Chantix® is a registered trademark of Pfizer Inc.

    SOURCE: Achieve Life Sciences, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/631465/Achieve-Life-Sciences-Announces-Presentation-of-Data-on-Smoker-and-E-Cigarette-User-Attitudes-and-Perceptions-on-Quitting-at-the-Society-for-Research-on-Nicotine-Tobacco-SRNT-Annual-Meeting

    View Full Article Hide Full Article
  2. SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / February 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will present at the MicroCap Rodeo Winter Wonderland Conference, which is being held virtually on February 16th - 19th, 2021.

    Mr. John Bencich, Chief Executive Officer of Achieve Life Sciences, is scheduled to present on Tuesday, February 16th at 12:30 p.m. EST, with one-on-one meetings to be held throughout the conference.

    The presentation will be webcast live and available for replay http://ir.achievelifesciences.com/events-and-webcasts. For registration…

    SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / February 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will present at the MicroCap Rodeo Winter Wonderland Conference, which is being held virtually on February 16th - 19th, 2021.

    Mr. John Bencich, Chief Executive Officer of Achieve Life Sciences, is scheduled to present on Tuesday, February 16th at 12:30 p.m. EST, with one-on-one meetings to be held throughout the conference.

    The presentation will be webcast live and available for replay http://ir.achievelifesciences.com/events-and-webcasts. For registration information and meeting requests please visit https://microcaprodeo.com/signup.

    About the MicroCap Rodeo Winter Wonderland Conference
    The MicroCap Rodeo Winter Wonderland conference is a virtual event showcasing 35 best ideas from the buy side. Qualified institutional investors recommended each of the 35 companies represented.

    About Achieve and Cytisinicline
    Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the U.S. annually.1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2

    Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.

    Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

    As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.

    Investor Relations Contact
    Jason Wong

    (415) 375-3340 ext. 4

    Media Contact
    Glenn Silver

    (646) 871-8485

    References
    1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.

    2 U.S. Department of Health and Human Services. The Health Consequences of Smoking - 50 Years of Progress. A Report of the Surgeon General, 2014.

    SOURCE: Achieve Life Sciences, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/629219/Achieve-Life-Sciences-to-Present-at-the-MicroCap-Rodeo-Winter-Wonderland-Conference-on-February-16-2021

    View Full Article Hide Full Article
  3. SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / January 7, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that John Bencich, Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference being held virtually January 11-14, 2021.

    A webcast of the presentation will be available on Monday, January 11th at 6:00 AM EST and can be accessed by visiting the Achieve Investor Relations page http://ir.achievelifesciences.com/events-and-webcasts.

    About Achieve and Cytisinicline
    Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million…

    SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / January 7, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that John Bencich, Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference being held virtually January 11-14, 2021.

    A webcast of the presentation will be available on Monday, January 11th at 6:00 AM EST and can be accessed by visiting the Achieve Investor Relations page http://ir.achievelifesciences.com/events-and-webcasts.

    About Achieve and Cytisinicline
    Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the U.S. annually.1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2

    Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.

    Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

    As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.

    Investor Relations Contact
    Jason Wong

    (415) 375-3340 ext. 4

    References

    1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.

    2 U.S. Department of Health and Human Services. The Health Consequences of Smoking - 50 Years of Progress. A Report of the Surgeon General, 2014.

    SOURCE: Achieve Life Sciences, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/623186/Achieve-Life-Sciences-to-Present-at-HC-Wainwright-Virtual-BioConnect-Conference

    View Full Article Hide Full Article
  4. SEATTLE and VANCOUVER, B.C., Dec. 7, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the closing of an underwritten public offering of 2,472,500 shares of its common stock at a public offering price of $7.00, for total  gross proceeds of $17.3 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. This includes the full exercise of the underwriter's over-allotment option to purchase an additional 322,500 shares of common stock.

    SEATTLE and VANCOUVER, B.C., Dec. 7, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the closing of an underwritten public offering of 2,472,500 shares of its common stock at a public offering price of $7.00, for total  gross proceeds of $17.3 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. This includes the full exercise of the underwriter's over-allotment option to purchase an additional 322,500 shares of common stock.

    Achieve intends to use the proceeds from the offering to fund its Phase 3 ORCA-2 trial, clinical research and development, as well as for working capital and general corporate purposes. The capital from this financing extends the Company's cash runway into mid-2022.

    Lake Street Capital Markets LLC acted as the sole bookrunning manager in the offering. Maxim Group LLC served as the co-manager.

    The securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-250074), which was declared effective by the Securities and Exchange Commission (SEC) on December 2, 2020.

    This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A final prospectus relating to this offering was filed by Achieve with the SEC. Copies of the final prospectus can be obtained at the SEC's website at www.sec.gov or from Lake Street Capital Markets LLC, Prospectus Department, 920 Second Avenue South, Suite 700, Minneapolis, Minnesota 55402 or by email at .

    About Achieve and Cytisinicline

    Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide. and nearly half a million deaths in the U.S. annually.12 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2 Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and Achieve's registration statement on Form S-1 (File No. 333-250074), as amended, and Form S-1MEF (File No. 333-251088). Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

    Achieve Contact

    Jason Wong



    (415) 375-3340 ext. 4

    ______________________

    1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.

    2 U.S. Department of Health and Human Services. The Health Consequences of Smoking - 50 Years of Progress. A Report of the Surgeon General, 2014.

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/achieve-life-sciences-inc-announces-closing-of-17-3-million-underwritten-public-offering-including-full-exercise-of-overallotment-option-301187685.html

    SOURCE Achieve Life Sciences, Inc.

    View Full Article Hide Full Article
  5. SEATTLE and VANCOUVER, B.C., Dec. 3, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of 2,150,000 shares of its common stock at a price to the public of $7.00 per share. The aggregate gross proceeds from this offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other offering expenses payable by Achieve. Achieve has also granted the underwriters a 30-day option to purchase up to an additional 322,500 shares of common stock in connection with the…

    SEATTLE and VANCOUVER, B.C., Dec. 3, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of 2,150,000 shares of its common stock at a price to the public of $7.00 per share. The aggregate gross proceeds from this offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other offering expenses payable by Achieve. Achieve has also granted the underwriters a 30-day option to purchase up to an additional 322,500 shares of common stock in connection with the public offering.  All of the securities are being offered by Achieve. The offering is expected to close on or about December 7, 2020, subject to the satisfaction of customary closing conditions. 

    Lake Street Capital Markets LLC is acting as the sole bookrunning manager in the offering. Maxim Group LLC is serving as the co-manager.

    Achieve intends to use the proceeds from the offering to fund its Phase 3 ORCA-2 trial, clinical research and development, as well as for working capital and general corporate purposes.

    The securities are being offered by Achieve pursuant to a registration statement on Form S-1 (File No. 333-250074) declared effective by the Securities and Exchange Commission (SEC) on December 2, 2020, and the registration statement filed by the Company with the SEC on December 2, 2020 pursuant to Rule 462(b). The offering is being made only by means of a prospectus included in the registration statement, copies of which may be obtained from: Lake Street Capital Markets LLC, Prospectus Department, 920 Second Avenue South, Suite 700, Minneapolis, Minnesota 55402 or by email at . When available, electronic copies of the final prospectus may be obtained for free by visiting the website of the SEC at http://www.sec.gov.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Achieve, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

    About Achieve and Cytisinicline

    Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide. and nearly half a million deaths in the U.S. annually.1 2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.2 Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements Achieve makes regarding the ability to complete the offering, potential exercise of the overallotment option, expected use of proceeds, potential benefits of Achieve's product candidates and platform and potential market opportunities for Achieve's product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. There can be no assurance regarding the completion of the offering. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, and others described in Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, and Achieve's registration statement on Form S-1 (File No. 333-250074). Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

    Achieve Contact

    Jason Wong



    (415) 375-3340 ext. 4

    1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.

    2 U.S. Department of Health and Human Services. The Health Consequences of Smoking - 50 Years of Progress. A Report of the Surgeon General, 2014.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/achieve-life-sciences-announces-pricing-of-15-million-public-offering-301185305.html

    SOURCE Achieve Life Sciences, Inc.

    View Full Article Hide Full Article
View All Achieve Life Sciences Inc. News